Overview
The objective of this study is to explore the integration of in vivo and ex vivo of MRI with histology and molecular assessments to advance non-invasive characterization of tumor heterogeneity in high-grade serous ovarian cance
Description
After being informed about the study and potential risks, all patient giving wirtting informed consent.
During surgery, tissue and blood samples will be conserved for the study. In this study will be compared images obtained in vivo before surgical management, ex vivo images obtained on excised tissues during surgery, histological data obtained during surgery.
Eligibility
Inclusion Criteria:
- Patient aged >18
- Pathologically proven HGSOC at an advanced stage (FIGO IIIB or IIIC) which can benefit from surgery with or without prior neoadjuvant treatment
- Willingness and ability to comply with planned visits, treatment plan, laboratory tests and other study procedures,
- Patient who has given informed, written and express consent,
- Patient affiliated with a French health insurance scheme.
Exclusion Criteria:
- Early-stage disease (FIGO <IIIB) or presence of extraperitoneal metastases,
- Patient who will not have surgery
- Patient whose regular follow-up is impossible for psychological, family, social or geographical reasons,
- Patient under guardianship, curatorship or safeguarding of justice,
- Pregnant and/or nursing patient,
- Patient with a history of other cancers within 5 years/10 years prior to inclusion